Asthma Peak Week is Approaching
September is a peak time for asthma attacks in the United States. According to the Allergy and Asthma Network, this is when emergency department visits and hospital admissions for asthma…
Lung Health Education Series – Free ALA Resource
INHALE is pleased to share details on a new, free educational resource American Lung Association (ALA) is offering through their Lung HelpLine, Lung Health Education Series.
Replacing Albuterol Rescue Inhalers – Audiocast CME Opportunity
Listen and learn from Dr. Reuben Strayer, emergency medicine physician in New York, about how providers can improve their patient outcomes by replacing Albuterol rescue inhalers.
The report is updated yearly and is based, to the best of the group’s ability, on current best evidence, medical knowledge, and practice. Since 2019, when there was a major…
The 2024 and 2025 INHALE Timelines Are Now Available
The 2024 and 2025 timelines are now available, view them here. We have split the timelines into Cohort 1 (PO's starting in 2022) and Cohort 2 (POs starting in 2024).…
Teva to Discontinue Digital Inhalers
Teva Pharmaceuticals is discontinuing its series of digital inhalers starting June 1, 2024. Teva’s digital inhalers include: ProAir® Digihaler® (albuterol sulfate) inhalation powderArmonAir® Digihaler® (fluticasone propionate) inhalation powderAirDuo® Digihaler® (fluticasone…
Drug Companies Step Forward with Voluntary Price Caps on Inhalers
Drug companies Boehringer Ingelheim, AstraZeneca and GSK have announced they are capping out-of-pocket costs for their inhaler products at $35 per month. INHALE applauds all three companies for their decision!…
MEDICATION UPDATE: Inhaled Medication Coverage Changes
BCBSM Update BCBSM approves Flovent ABA for members less than 5 years of age. No prior authorization needed for the 44mcg HFA to bridge coverage due to the Amsmanex inhaler…
General Update Flovent HFA and Flovent Diskus are inhaled corticosteroid medicines used as a controller medicine to treat asthma. Flovent HFA is also used to treat eosinophilic esophagitis (EoE). Glaxo…
INHALE Hosts Inaugural Patient Advisory Board Meeting
The INHALE Patient Advisory Board assembled for its first virtual meeting on November 9th. At this meeting, the group discussed goals of the board, operating norms, meeting cadence, and each advisor’s “why”…
Reduce reliance on short-acting beta-agonists and oral corticosteroid overuse to improve disease control, reduce exacerbations and long-term adverse effects
Education for both providers and patients on proper inhaler use; recognition of good disease control and measures to reduce acute exacerbations
Improving access to and the appropriate use of spirometry as a tool to accurately diagnose both Asthma and COPD
Proactively focusing on risk mitigation and exacerbation reduction in addition to enhancing our ability to achieve disease control
INHALE prepares regular PO and Clinical level newsletters that contain:
Support for the INHALE CQI is provided by Blue Cross Blue Shield of Michigan as part of the BCBSM Value Partnerships program. BCBSM’s Value Partnerships program provides clinical and executive support for all CQI programs.
Although Blue Cross Blue Shield of Michigan and the INHALE CQI work in partnership, the opinions, beliefs, and viewpoints expressed by INHALE CQI do not necessarily reflect the opinions, beliefs, and viewpoints of BCBSM or any of its employees.